FCA Corp TX Buys Shares of 7,500 AstraZeneca PLC $AZN

Key Points

• FCA Corp TX has acquired a new position in AstraZeneca PLC, purchasing 7,500 shares valued at approximately $551,000 in the first quarter.
• AstraZeneca's shares have recently seen a 3.5% increase, reflecting a market cap of $241.72 billion and a P/E ratio of 29.30.
• The company also recently declared a $0.505 dividend with a dividend yield of 200.0%, although it has faced a decrease in year-over-year EPS from $1.24 to $1.09.

FCA Corp TX purchased a new stake in AstraZeneca PLC (NASDAQ:AZN - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 7,500 shares of the company's stock, valued at approximately $551,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Lindbrook Capital LLC increased its position in AstraZeneca by 1.9% in the 1st quarter. Lindbrook Capital LLC now owns 7,574 shares of the company's stock valued at $557,000 after acquiring an additional 141 shares in the last quarter. Principal Securities Inc. grew its stake in shares of AstraZeneca by 0.5% during the first quarter. Principal Securities Inc. now owns 28,053 shares of the company's stock valued at $2,062,000 after purchasing an additional 142 shares during the last quarter. Sage Mountain Advisors LLC increased its holdings in shares of AstraZeneca by 3.4% in the first quarter. Sage Mountain Advisors LLC now owns 4,478 shares of the company's stock valued at $329,000 after purchasing an additional 147 shares in the last quarter. CoreCap Advisors LLC raised its position in AstraZeneca by 31.8% in the 4th quarter. CoreCap Advisors LLC now owns 642 shares of the company's stock worth $42,000 after purchasing an additional 155 shares during the last quarter. Finally, Oakworth Capital Inc. raised its position in AstraZeneca by 2.0% in the 1st quarter. Oakworth Capital Inc. now owns 8,575 shares of the company's stock worth $630,000 after purchasing an additional 167 shares during the last quarter. Institutional investors and hedge funds own 20.35% of the company's stock.

AstraZeneca Trading Up 0.7%

AstraZeneca stock traded up $0.5450 during mid-day trading on Tuesday, hitting $79.6650. The stock had a trading volume of 1,644,285 shares, compared to its average volume of 5,288,587. The stock has a 50-day simple moving average of $72.44 and a two-hundred day simple moving average of $71.97. The stock has a market capitalization of $247.07 billion, a PE ratio of 29.95, a P/E/G ratio of 1.46 and a beta of 0.36. AstraZeneca PLC has a 12 month low of $61.24 and a 12 month high of $87.68. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.55.

AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $1.09 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.09. AstraZeneca had a return on equity of 32.84% and a net margin of 14.68%.The business had revenue of $14.46 billion for the quarter, compared to analysts' expectations of $14.08 billion. During the same quarter last year, the business earned $1.24 earnings per share. The firm's quarterly revenue was up 16.1% compared to the same quarter last year. As a group, sell-side analysts forecast that AstraZeneca PLC will post 4.51 EPS for the current year.

AstraZeneca Cuts Dividend

The business also recently announced a semi-annual dividend, which will be paid on Monday, September 8th. Shareholders of record on Friday, August 8th will be paid a $0.505 dividend. The ex-dividend date of this dividend is Friday, August 8th. This represents a yield of 200.0%. AstraZeneca's dividend payout ratio is presently 37.97%.

Wall Street Analysts Forecast Growth

Separately, Berenberg Bank set a $97.00 target price on AstraZeneca in a research note on Wednesday, July 9th. Four research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat.com, AstraZeneca has an average rating of "Moderate Buy" and an average price target of $86.00.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.